LEXINGTON, Massachusetts, November 18 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will today hold its analysts and investors seminar on its Human Genetic Therapies business (Shire HGT).
The seminar will be webcast and all the slides presented during this seminar are available on http://www.shire.com.
As part of the seminar, Angus Russell, Chief Executive of Shire plc, will comment on the company's longer term strategic aim to become the leading specialty biopharmaceutical company focusing on meeting the needs of the specialist physician.
To achieve this, Shire aims to: